Publications by authors named "Alejandro Perez Fidalgo"

Claim this Profile
S
SEOM-GEICO clinical guidelines on endometrial cancer (2025).
Sara Pérez Ramírez, Alejandro Pérez Fidalgo, María Pilar Barretina Ginesta, Ana De Juan Ferré, Lorena Fariñas Madrid

Clin Transl Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
Philipp Harter, Frederik Marmé, Andrés Redondo, Alexander Reuss, Kristina Lindemann, J Alejandro Pérez-Fidalgo

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking Personality Traits to Mediterranean Diet Adherence and Exploring Gene-Diet Interactions in Neuroticism.
José V Sorlí, Carolina Ortega-Azorín, Oscar Coltell, Rebeca Fernández-Carrión, Eva M Asensio, Alejandro Perez-Fidalgo

Nutrients· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.
Alejandro Pérez Fidalgo, Pilar Alonso, Maitane Andión, Adela Cañete, Erica Collado

Clin Transl Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.
Alejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, Charlie Gourley, Sandro Pignata

Int J Gynecol Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
Guillermo Villacampa, Gemma Eminowicz, Victor Navarro, Lorenzo Carità, David García-Illescas, J Alejandro Pérez-Fidalgo

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
Antonio González-Martín, María Jesús Rubio, Florian Heitz, René Depont Christensen, Nicoletta Colombo, J Alejandro Pérez-Fidalgo

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depression and Accelerated Aging: The Eveningness Chronotype and Low Adherence to the Mediterranean Diet Are Associated with Depressive Symptoms in Older Subjects.
José V Sorlí, Edurne de la Cámara, Rebeca Fernández-Carrión, Eva M Asensio, Olga Portolés, Alejandro Pérez-Fidalgo

Nutrients· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.
Jalid Sehouli, Jolijn Boer, Alison H Brand, Amit M Oza, Jennifer O'Donnell, Alejandro Perez Fidalgo

Int J Gynecol Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog

Int J Gynecol Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors.
Christian S Alvarez, M Blanca Piazuelo, Tania Fleitas-Kanonnikoff, Jennifer Ruhl, J Alejandro Pérez-Fidalgo

JAMA Netw Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Alejandro Pérez-Fidalgo

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Alejandro Pérez-Fidalgo

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, Sherene Loi, Aditya Bardia, J Alejandro Pérez-Fidalgo

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy.
Sergio Cedillo, Carla Garí, Susana Aceituno, Luis Manso, Ana Cristina Cercos Lleti, Alejandro Perez Fidalgo

Int J Gynecol Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, Guillermo Villacampa, Munetaka Takekuma, J Alejandro Pérez-Fidalgo

Lancet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between the New DNA-Methylation-Based Telomere Length Estimator, the Mediterranean Diet and Genetics in a Spanish Population at High Cardiovascular Risk.
Oscar Coltell, Eva M Asensio, José V Sorlí, Carolina Ortega-Azorín, Rebeca Fernández-Carrión, Alejandro Pérez-Fidalgo

Antioxidants (Basel)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus.
Andrés Redondo, Pilar Barretina, Alejandro Pérez-Fidalgo, María Jesús Rubio, Antonio González-Martín

J Gynecol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA-Methylation Signatures of Tobacco Smoking in a High Cardiovascular Risk Population: Modulation by the Mediterranean Diet.
Rebeca Fernández-Carrión, José V Sorlí, Eva M Asensio, Eva C Pascual, Olga Portolés, Alejandro Pérez-Fidalgo

Int J Environ Res Public Health· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of Meals and Sleep in the Mediterranean Population: The Effect of Taste, Genetics, Environmental Determinants, and Interactions on Obesity Phenotypes.
Rocío Barragán, Rebeca Fernández-Carrión, Eva María Asensio-Márquez, Carolina Ortega-Azorín, Andrea Álvarez-Sala, Alejandro Pérez-Fidalgo

Nutrients· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model.
Paula Montero, Javier Milara, Martín Pérez-Leal, Cristina Estornut, Inés Roger, Alejandro Pérez-Fidalgo

Int J Mol Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.
Valentina Gambardella, Pasquale Lombardi, Juan Antonio Carbonell-Asins, Noelia Tarazona, Juan Miguel Cejalvo, Alejandro Pérez-Fidalgo

Br J Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L Alves, Anna Ehinger, Alejandro Pérez-Fidalgo

Breast Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, J Alejandro Pérez-Fidalgo

Breast Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.
Eleftherios P Samartzis, S Intidhar Labidi-Galy, Michele Moschetta, Mario Uccello, Dimitrios R Kalaitzopoulos, J Alejandro Perez-Fidalgo

Ann Transl Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis